Key Appointment At MSD China Shows Long-Term Investment
This article was originally published in PharmAsia News
Executive Summary
Merck, Sharpe & Dohme recently appointed health care veteran Michel Vounatsos as MSD China president. Before coming to China, he was president of MSD France, one of the firm's most important markets outside the U.S. The current appointment shows the company's long-term investment and commitment in China as well as the country's strategic importance for MSD. Vounatsos said China is a key market for MSD; the firm will continue to provide innovative drugs and services for Chinese customers as well as offer full support to the nation's health care reform. (Click here for more - Chinese language)